<SEC-DOCUMENT>0000950170-24-076972.txt : 20240624
<SEC-HEADER>0000950170-24-076972.hdr.sgml : 20240624
<ACCEPTANCE-DATETIME>20240624190434
ACCESSION NUMBER:		0000950170-24-076972
CONFORMED SUBMISSION TYPE:	144/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240624
DATE AS OF CHANGE:		20240624

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mereo BioPharma Group plc
		CENTRAL INDEX KEY:			0001719714
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38452
		FILM NUMBER:		241065839

	BUSINESS ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF
		BUSINESS PHONE:		4403330237300

	MAIL ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mereo Biopharma Group plc
		DATE OF NAME CHANGE:	20171016

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lewicki John A.
		CENTRAL INDEX KEY:			0001553352
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144/A

	MAIL ADDRESS:	
		STREET 1:		C/O ONCOMED PHARMACEUTICALS, INC.
		STREET 2:		800 CHESAPEAKE DRIVE
		CITY:			REDWOOD CITY
		STATE:			MA
		ZIP:			94063
</SEC-HEADER>
<DOCUMENT>
<TYPE>144/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144/A</submissionType>
<previousAccessionNumber>0000950170-24-075613</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001553352</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001719714</issuerCik>
<issuerName>Mereo BioPharma Group plc</issuerName>
<secFileNumber>001-38452</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">4th Floor, One Cavendish Place</street1>
<city xmlns="http://www.sec.gov/edgar/common">London</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">X0</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">W1G 0QF</zipCode>
</issuerAddress>
<issuerContactPhone>44-333 023 7300</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Lewicki John A.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Officer</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>American Depositary Shares Representing Ordinary Shares</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Morgan Stanley &amp; Co. LLC</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">1585 Broadway</street1>
<city xmlns="http://www.sec.gov/edgar/common">New York</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">10036-8293</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>26647</noOfUnitsSold>
<aggregateMarketValue>106055.06</aggregateMarketValue>
<noOfUnitsOutstanding>765150254</noOfUnitsOutstanding>
<approxSaleDate>06/25/2024</approxSaleDate>
<securitiesExchangeName>Nasdaq</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>American Depositary Shares Representing Ordinary Shares</securitiesClassTitle>
<acquiredDate>06/21/2024</acquiredDate>
<natureOfAcquisitionTransaction>Same Day Cashless Exercise and Sale</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>69000</amountOfSecuritiesAcquired>
<paymentDate>06/21/2024</paymentDate>
<natureOfPayment>Equity Compensation</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<remarks>This form 144 amends and supersedes the form 144 filed on June 20, 2024. The name and address of the broker has been corrected.</remarks>
<noticeSignature>
<noticeDate>06/24/2024</noticeDate>
<signature>/s/ John A. Lewicki</signature>
</noticeSignature>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
